Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better?

I Pourmir1, R Nebbache2, S Champiat3

  • 1Thoracic Oncology Department, Georges Pompidou European Hospital, Paris CARPEM Cancer Institute, AP-HP Centre, Université Paris Cité, Paris; INSERM Immunotherapy and Anti-Angiogenic Therapy in Oncology, PARCC, Paris.

Abstract

No abstract available in PubMed .

Related Concept Videos